24/7 Market News Snapshot 22 July, 2025 – Cardiol Therapeutics Inc. Class A Common Shares (NASDAQ:CRDL)

July 22, 2025

DENVER, Colo., 22 July, 2025 (www.247marketnews.com) – (NASDAQ:CRDL) are discussed in this article.
Cardiol Therapeutics Inc., a clinical-stage life sciences company dedicated to developing innovative therapies for heart disease, is experiencing notable market activity, with its stock opening at $1.23 and currently trading at $1.435, reflecting a significant 17.62% increase. This upward trajectory follows a previous close of $1.22, driven by strong investor interest demonstrated through a trading volume of 714.97K. Technical indicators point to a bullish momentum, suggesting that further gains may be on the horizon as the price surpasses short-term resistance levels, warranting careful observation of volume trends and support levels by traders.

In addition to its stock performance, Cardiol has announced a critical milestone in its Phase II clinical trial known as ARCHER, which evaluates CardiolRx™, the company’s lead cannabinoid product, for its efficacy in enhancing myocardial recovery in patients suffering from acute myocarditis. This multi-national, randomized, double-blind, placebo-controlled study has achieved its database lock, allowing for statistical analysis and facilitating the upcoming unblinding of results. Topline findings are expected to be released in the next two weeks, offering pivotal insights into the potential of CardiolRx™.

President and CEO David Elsley expressed enthusiasm for this significant achievement, stating that the results will not only deepen understanding of cardiac health but also influence the company’s broader strategies in treating heart disease. Given that acute myocarditis is linked to severe health risks, including heart failure, the results could pave the way for new pharmacological interventions in an area currently lacking FDA-approved treatments.

Chief Medical Officer Dr. Andrew Hamer highlighted the importance of these findings for improving the management of acute myocarditis, emphasizing the contributions of study participants and clinical investigators. As Cardiol’s efforts continue, the company remains committed to further programs, including the MAVERIC trial for recurrent pericarditis, with insights from ARCHER poised to advance its initiatives in cardiovascular care.

Related news for (CRDL)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.